Efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma: A Meta-analysis / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1397-1403, 2024.
Article
en Zh
| WPRIM
| ID: wpr-1038656
Biblioteca responsable:
WPRO
ABSTRACT
ObjectiveTo systematically evaluate the efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma. MethodsThis study was conducted according to PRISMA guidelines, with a PROSPERO registration number of CRD42023488398. PubMed, Embase, Web of Science, the Cochrane Library, CNKI, Wanfang Data, VIP, and CBM were searched for Chinese and English articles on three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma published up to March 2023. After quality assessment and data extraction of the studies included, RevMan 5.4 software was used to perform the meta-analysis. ResultsA total of 11 studies were included, with 972 patients in total, among whom 447 underwent ablation assisted by three-dimensional visualization technology (3D group) and 525 underwent ablation assisted by traditional two-dimensional imaging technology (2D group). The meta-analysis showed that compared with the 2D group, the 3D group had significantly higher success rate of first-time ablation treatment (odds ratio [OR]=5.43, 95% confidence interval [CI]: 2.64 — 11.18, P<0.001), technical efficiency (OR=6.15, 95%CI: 3.23 — 11.70, P<0.001), and complete ablation rate (OR=2.50, 95%CI: 1.08 — 5.78, P=0.03), as well as significantly lower incidence rate of major complications (OR=0.45, 95%CI: 0.24 — 0.87, P=0.02), local recurrence rate (OR=0.35, 95%CI: 0.17 — 0.72, P=0.004), and local tumor progression rate (OR=0.29, 95%CI: 0.16 — 0.50, P<0.001), while there was no significant difference in the incidence rate of mild complications between the two groups (P>0.05). ConclusionThree-dimensional visualization technology is safe and feasible in assisting ablation therapy for hepatocellular carcinoma and can improve ablation rate and reduce the incidence rate of serious complications, local recurrence rate, and local tumor progression rate, thereby showing an important application value in clinical practice.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Clinical Hepatology
Año:
2024
Tipo del documento:
Article